Cohort name (N) | Therapy | Cancer | # slides per patient† | Histology (Stage I, II, III, IV, missing) | #Alive (# dead) | Mean age±std | Site |
D0* (51) | Chemotherapy | Ovarian | 1–2 | HGSOC (2, 4, 73, 23, 1) | 32 (71) | 61.41±11.2 | TCGA |
D1 (52) | Chemotherapy | ||||||
D2 (140) | Chemotherapy | Cervical | 1–4 | Adenocarcinomas, squamous cell carcinoma (140, 61, 42, 20, 6) | 204 (65) | 48.17±13.3 | |
D3 (129) | Radiotherapy | ||||||
D4 (261) | Chemotherapy | Endometrial | 1–8 | Endometrioid carcinomas, serous cystadenocarcinoma, clear cell, and undifferentiated (319, 48, 110, 28, 0) | 424 (81) | 63.85±11.1 | |
D5 (244) | Radiotherapy | ||||||
D6 (14) | Immunotherapy | Ovarian | 1 | HGSOC, clear cell (1, 2, 5, 5,1) | 19 (30) | 63.3±13.1 | CCF |
D7 (8) | Immunotherapy | Cervical | 1 | Squamous cell carcinoma (0, 0, 4, 3,1) | 63.10±13.7 | ||
D8 (27) | Immunotherapy | Endometrial | 1 | Endometrioid, serous, clear cell (12, 0, 8, 5,2) | 71.3±9.1 |
*The range is shown, and the median number of slides in all groups is 1.
†Indicate training cohort.
CCF, Cleveland Clinic Foundation; HGSOC, high-grade serous ovarian cancer ; TCGA, The Cancer Genome Atlas .